Health
Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds – News-Medical.Net
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
Vaccination against coronavirus disease 2019 (COVID-19) has been considered to be the most effective way to reduce the mortality and morbidity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Several vaccine candidates have…
Continue Reading
-
Noosa News22 hours ago‘Just want to know he’s safe’: Family’s German Shepherd asleep in back of stolen ute
-
Noosa News22 hours agoDriver acquitted of murder over lengthy road-rage chase
-
General20 hours agoMitchell Starc fires Ashes warning in Sheffield Shield return as Jake Weatherald and Beau Webster fail to fire
-
Noosa News22 hours agoFather in custody after horror crash kills partner and daughter in Doomadgee